Trial Profile
Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary)
- Indications Giant lymph node hyperplasia; Multiple myeloma
- Focus Pharmacodynamics
- 16 Jan 2018 Status changed from active, no longer recruiting to completed.
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2016 Status changed from not yet recruiting to recruiting.